BPC-157 Frequently Asked Questions
Compiled from common user questions and recurring confusions in the research literature.
Regulatory and trial status at a glance: three human pilot completions (blue), one critical non-approval status (red).
Compound and Mechanism
BPC-157 is a 15-amino-acid synthetic peptide (pentadecapeptide) with the sequence GEPPPGKPADDAGLV and a molecular weight of 1419.5 Da. It is derived from a protein found in human gastric juice — specifically from a body protection compound identified in the stomach's cytoprotective secretions. The peptide was not discovered in human plasma or tissue at physiologically active concentrations; it is a research compound isolated and synthesized from the gastric source protein. Its synonyms in the published literature include Pentadecapeptide BPC 157, PL 14736, and Bepecin. It has no approved human indication anywhere in the world.
The primary documented mechanism operates through the VEGFR2-Akt-eNOS signaling axis. [7][8][13] Activation of this pathway promotes context-appropriate angiogenesis and endothelial nitric oxide production in injured tissue. Alongside this, BPC-157 has been documented to: upregulate growth hormone receptor expression in tendon fibroblasts by up to 7-fold, potentiating GH-induced cell proliferation via JAK2 [2]; activate FAK-paxillin signaling to enhance fibroblast migration and collagen deposition [17]; activate ERK1/2 for endothelial proliferation and tube formation [17]; and modulate NF-kB, dopaminergic, and serotonergic pathways in neurological injury models. [9][10] A 2025 systematic review of 36 studies confirmed VEGFR2-Akt-eNOS, ERK1/2, and FAK-paxillin as the primary pathways in musculoskeletal repair models. [17]
Twenty cataloged preclinical findings span tendon, ligament, muscle, bone, wound/burn, vascular, and neurological injury models — primarily in rats, with rabbit and pig data for bone and wound models respectively. Consistent findings: BPC-157 groups demonstrate faster repair, superior biomechanical outcomes, normalized biochemical injury markers, and reduced macroscopic damage versus saline controls.
Notable results include: full Achilles tendon integrity reestablished by day 14 [1]; MCL healing improvement through 90 days across IP, oral, and topical routes [3]; muscle-to-bone reattachment confirmed by MRI at day 21–28 after complete quadriceps detachment [18]; and bone defect healing comparable to autologous graft at 6 weeks in rabbits. [6] Most primary research originates from the Sikiric group at the University of Zagreb; independent replication by separate research groups is limited — an acknowledged limitation in the 2025 systematic review. [17]
The published preclinical literature spans six primary tissue and organ categories: musculoskeletal (tendon, [1][2] ligament, [3] muscle, [5][18] bone [6]); gastrointestinal mucosal (GI cytoprotection, fistula healing [4]); vascular and endothelial (major vessel occlusion, ischemia-reperfusion, portal hypertension, intra-abdominal hypertension [8][12]); wound healing (incisional, excisional, burn, diabetic ulcer [4]); neurological (dopaminergic and serotonergic system modulation [9][10]); and angiogenic regulation (context-dependent pro- and anti-angiogenic activity [7][13]). The breadth across tissue types is why the compound is described as pleiotropic — one peptide, multiple tissue contexts.
BPC-157 was found to increase growth hormone receptor (GHR) mRNA and protein expression by up to 7-fold in rat Achilles tendon fibroblasts over three days at concentrations of 0.1–0.5 μg/mL in cell culture. [2] This GHR upregulation enhanced subsequent GH-induced cell proliferation via JAK2 phosphorylation — meaning BPC-157 may amplify the fibroblast response to endogenous GH signals. This is a cell-culture finding; no in vivo co-administration study in intact animals or humans has confirmed this interaction, so the mechanistic implication for in vivo healing remains speculative based on the current published evidence.
Context-dependent modulation is a defining feature of BPC-157's documented mechanism. In injured musculoskeletal tissue, it promotes angiogenesis via VEGFR2 signaling. [7] In pathological corneal neovascularization, it inhibits angiogenesis. [13] In major vessel occlusion, it recruits collateral pathways to restore perfusion. [8] In nitric oxide states, it increases NO when deficient and decreases it when excess. [13] The 2025 Pharmaceuticals review describes this as "beneficial pleiotropic effect controlling and modulating angiogenesis and the NO-system" — the compound appears to normalize rather than uniformly stimulate or suppress the pathways it engages. Whether this context-dependence is intrinsic to the peptide's receptor interactions or mediated by tissue-specific co-factors is not yet established.
Dosing and Pharmacokinetics
The most common intraperitoneal dose ladder in rodent studies uses 10 μg/kg, 10 ng/kg, and 10 pg/kg — spanning a 10,000,000-fold range from picogram to microgram. Multiple studies show efficacy across the full range, including at the picogram dose. [4][13] Oral delivery typically uses 10 μg/kg/day and 10 ng/kg/day in drinking water. Topical cream studies use 1 μg/g. No toxic dose has been established up to 20 mg/kg in rats. [20] These are research-context parameters from published animal studies — not dosing recommendations for any human or animal clinical use.
Formal PK characterization in Sprague-Dawley rats and beagle dogs (He et al., 2022) [11] documented: elimination half-life less than 30 minutes in both species via IV and IM routes; Cmax at 3–9 minutes post-IM injection; IM bioavailability of 14–19% in rats and 45–51% in dogs; linear dose-proportional kinetics across the full dose ladders tested. Highest tissue concentrations post-IV were found in kidney, liver, and stomach. Excretion is primarily via urine and bile through rapid peptide fragmentation. Despite the short half-life, in vivo tissue repair efficacy in published studies persisted to day 14, 28, and 90 — suggesting rapid receptor engagement initiates downstream transcriptional cascades that outlast systemic plasma presence.
BPC-157 demonstrates documented stability in the gastric acid and peptic environment — an unusual characteristic for a therapeutic peptide. This property, attributed to its gastric-protein origin, enables per-oral delivery without a protective formulation or carrier. [20] Multiple preclinical studies delivered BPC-157 via oral gavage or in drinking water and found results comparable to intraperitoneal injection in matched healing models. [3][18] However, oral bioavailability has not been formally quantified by pharmacokinetic AUC methods — the oral efficacy data is functional (tissue outcomes) without a documented bioavailability percentage comparable to the IM data (14–19% rat, 45–51% dog). Whether oral gastric stability translates directly to absorbed systemic exposure remains incompletely characterized in the published PK literature.
The 2025 literature and patent review [20] identified gastric acid stability as a key formulation advantage, enabling oral delivery. Ten active patents were documented for novel BPC-157 formulations and combination therapies. The review also noted that peptide purity and stability in commercial research-grade preparations can vary — a concern raised independently in the 2026 review [21] as a factor that complicates interpretation of self-reported or non-controlled results. The rapid systemic elimination (t½ <30 min) means that depot or controlled-release formulation could potentially address the half-life constraint — this is reflected in the patent landscape per the 2025 review. [20]
Human Evidence
Three published human pilot studies exist as of 2026. [14][15][16] The knee pain study (Lee & Padgett, 2021, n=16) reported 87.5% significant pain relief at 6–12 months following intra-articular injection. [16] The interstitial cystitis study (Lee et al., 2024, n=12) reported 80–100% symptom resolution at 6 weeks after a single 10 mg intravesical injection. [15] The IV safety pilot (Lee & Burgess, 2025, n=2) reported no adverse events and plasma clearance within 24 hours after 10 mg and 20 mg IV infusions. [14] None of these are randomized controlled trials. One Phase II trial of PL 14736 (enema form, ulcerative colitis) was conducted but not published in a peer-reviewed journal. NCT02637284 was registered in 2015 but not completed.
One published human pilot combined BPC-157 with TB-500 (Thymosin Beta-4) via intra-articular injection for knee pain (Lee & Padgett, 2021). [16] Because the study did not isolate BPC-157 and TB-500 conditions, the individual contribution of each compound cannot be determined from the published data. Mechanistically, the two compounds operate through distinct pathways — BPC-157 primarily via VEGFR2-Akt-eNOS and FAK-paxillin, TB-500 via actin-based cell migration — making a complementary interaction plausible from a pharmacological standpoint. No controlled combination studies have been conducted. GH co-administration has been proposed based on the GHR upregulation finding, [2] but no in vivo GH + BPC-157 co-administration study has been published.
The 2026 Yuan et al. review [21] and the 2025 Vasireddi et al. systematic review [17] both enumerate the same gaps: (1) No RCTs in humans; only three small unblinded pilots. (2) Most preclinical research originates from one group (Sikiric et al., University of Zagreb); independent replication is limited. (3) Oral bioavailability lacks formal PK quantification. (4) The short plasma half-life (<30 min) raises questions about dosing frequency needed for sustained efficacy. (5) Potential angiogenic promotion of tumor vascularization has been raised in the literature but not specifically studied. (6) Purity and stability of commercial research-grade preparations can vary; formulation differences may affect results.
Regulatory and WADA Status
BPC-157 is prohibited by the World Anti-Doping Agency under the S0 category — Non-Approved Substances on the Prohibited List. This prohibition applies at all times: in-competition and out-of-competition. No Therapeutic Use Exemption (TUE) pathway exists for non-approved substances. In 2024, an American speed skater received a 1-year sanction following BPC-157 product use. The compound is also listed on the DoD Prohibited Dietary Supplement Ingredients List for U.S. military service members. Any athlete subject to anti-doping testing who uses BPC-157 is at risk of sanction regardless of claimed therapeutic intent.
No approved human indication exists in the United States, European Union, or any other major regulatory jurisdiction. In the US, no active Investigational New Drug (IND) application is on file with the FDA. One Phase I trial registration (NCT02637284) was listed in 2015 but was not completed. In the EU, the related PL 14736 formulation was studied in Phase II for ulcerative colitis but results were never published in a peer-reviewed journal. BPC-157 is classified as a research chemical and is not approved for prescription, dispensing, or human consumption.